Greta Baltušytė

BRIDGE-AD integrates multimodal AD datasets to prioritize disease effectors, identifying 19 functional clusters and validating SCARB2 as a novel candidate.

This paper presents a network medicine framework integrating multi-modal data to identify therapeutic targets in clear cell renal cell carcinoma, recovering established targets and predicting five candidates, with ENO2 inhibition showing the strongest anti-tumour effect.

This paper develops a machine learning framework for therapeutic target discovery in ccRCC, identifying 16 targets and novel mechanisms with superior efficacy to standard-of-care drugs.